IntelGenx Technologies Corp. (NASDAQOTH:IGXT)

CAPS Rating: 2 out of 5

Recs

2
Player Avatar zzlangerhans (99.78) Submitted: 11/16/2011 1:08:36 AM : Underperform Start Price: $0.56 IGXT Score: +9.86

For a minute there I thought the market was wising up. After spiking as high as 0.72 in advance of their 11/13/11 PDUFA for spurious buproprion reformulation CPI-300, the share price dumped immediately after the open last Friday on news that CPI-300 had been approved. I figured smart traders had registered the fact that IntelGenx is soon going to be the company of NO - no cash, no partner, no sales. The share price bottomed at 0.48 on Monday morning but today a strange event occurred - buying. I don't know who these geniuses were that took the share price to 0.575 today but I was happy to take my win and reverse the flow on this stock as promised.

Report this Post 2 Replies
Member Avatar Stockhero (< 20) Submitted: 11/16/2011 1:59:08 AM
Recs: 0

Strong fundamentals here.. One of the cheapest Biotech Stock out there !

1) Very Very low Market cap of $23.5 M
2) Mega drug Pipeline of 9 Products including a potential Blockbuster
3) 2 New NDA filings in 2012
4) NO DEBT
5) Cash till 2014
6) Very strong Institutions and Insider in this stock holding over 50% of this Company
7) low float Stock

Intelgenx (IGXT.OB)

Market Cap : $26.1 M
Price: 0.56

Shares Out : 46 M (28 M shares held by Institutions and Insiders)

IntelGenx Announces FDA Approval of Its High Dose Anti-Depressant CPI-300
http://finance.yahoo.com/news/IntelGenx-Announces-FDA-pz-4172746127.html?x=0&l=1

Company Presentation
http://www.intelgenx.com/_assets/pdf/Intelgenx-Presentation.pdf

Ownership
http://data.cnbc.com/quotes/IGXT.OB/tab/8

interview with ceo
zerbe
http://www.cantechletter.com/2010/12/cantech-letter-interviews-horst-zerbe-president-and-ceo-of-intelgenx/

Article
http://www.biomedreports.com/2011111183312/fda-spproval-is-a-game-changer-for-intelgen

Upcoming Milestones
http://www.intelgenx.com/_assets/pdf/Intelgenx-FactSheet.pdf

Upcoming Milestones

Q4, 2011 Complete licensing agreement for CPI-300

Q4, 2011 Execute definitive agreement for new development and licensing VersaFilm project

Q4, 2011 Execute definitive agreement for bipolar disorder

Q4, 2011 Obtain FDA approval for CPI-300

Q2, 2012 Complete pivotal biostudy for anti-migraine VersaFilm

Member Avatar zzlangerhans (99.78) Submitted: 11/16/2011 12:39:10 PM
Recs: 3

Please go back to Yahoo.

Featured Broker Partners


Advertisement